Menu
← Oncology Approval Tracker
FDA DECISION ·
Palbociclib tablets
palbociclib · Synthon Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic 75 mg, 100 mg and 125 mg tablets for adults with HR-positive, HER2-negative advanced or metastatic breast cancer. Use with an aromatase inhibitor initially or with fulvestrant after progression on endocrine therapy.
LAMPGEN ANALYSIS
Why it matters
The FDA approved a generic tablet for the labeled endocrine-combination settings. FDA's signed initial approval letter is dated August 2023. The agency's 2024 listing references the same application and strengths.
What research teams should watch
Distinguish the approval date from market availability and verify whether a tablet or capsule is prescribed.
PRIMARY RECORDS